Quince Therapeutics CMO Karen Smith to depart effective Sept 1, 2023

Quince Therapeutics, Inc.

Chief Medical Officer Karen Smith, M.D., Ph.D. will depart on September 1, 2023.
Separation agreement includes 12 months base salary severance plus prorated 2023 bonus and health benefits lump sum.
Outstanding equity awards subject to 50% accelerated vesting; additional benefits if change in control occurs within 3 months after departure.
Dr. Smith will continue as employee until the departure date under transition and separation agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Karen Smith

Chief Medical Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2023-09-01
Filed: August 10, 2023, 7:59 PM ET

On July 24, 2023, Quince Therapeutics, Inc. (the “Company”) announced the departure of Karen Smith, M.D., Ph.D., the Company’s Chief Medical Officer, effective as of September 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen Smith departed as Chief Medical Officer at Quince Therapeutics, Inc..

Action: departure
Role: Chief Medical Officer

Exact text from the filing

On July 24, 2023, Quince Therapeutics, Inc. (the “Company”) announced the departure of Karen Smith, M.D., Ph.D., the Company’s Chief Medical Officer, effective as of September 1, 2023

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.